NCT04906993 2025-09-09
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
Jiangsu HengRui Medicine Co., Ltd.
ArriVent BioPharma, Inc.
Daiichi Sankyo